---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-041322"
form_type: "8-K"
ticker: "ELVN"
cik: "0001672619"
company_name: "Enliven Therapeutics, Inc."
filed_at: "2023-08-10T23:59:59+00:00"
generated_at: "2026-06-11T18:03:25.174408+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Enliven Therapeutics Q2 2023 net loss $16.7M; cash $277.9M; Phase 1 data expected 2024

## Summary
- Net loss of $16.7M for Q2 2023, compared to $8.9M in Q2 2022.
- Cash, cash equivalents and marketable securities total $277.9M as of June 30, 2023.
- R&D expenses $15.2M vs $7.9M; G&A expenses $5.0M vs $1.1M (year-over-year).
- Phase 1 trials for ELVN-001 (CML) and ELVN-002 (HER2+) advancing with initial safety/efficacy data expected in 2024.
- Third program product candidate selected; more details to be disclosed in 2024.

## SEC filing metadata
- accession: 0000950170-23-041322
- form_type: 8-K
- ticker: ELVN
- cik: 0001672619
- company_name: Enliven Therapeutics, Inc.
- filed_at: 2023-08-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1672619/000095017023041322/0000950170-23-041322-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1672619/000095017023041322/elvn-20230810.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-041322
- JSON: https://secwatch.observer/filing/0000950170-23-041322.json
- Plain text: https://secwatch.observer/filing/0000950170-23-041322.txt

## Key facts
- Earnings Releases
  Enliven Therapeutics, Inc. reported the second quarter ended June 30, 2023 results: net income $16.7 million.
  - Period: the second quarter ended June 30, 2023
  - Net income: $16.7 million
  - Result: reported results
  source text: Enliven reported a net loss of $16.7 million for the second quarter of 2023, compared to a net loss of $8.9 million for the second quarter of 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1672619/000095017023041322/0000950170-23-041322-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.